Status:
COMPLETED
IMUNOR® Preparation in the Prevention of COVID-19
Lead Sponsor:
University Hospital Ostrava
Conditions:
Covid19
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The aim of the study is to achieve prevention of COVID-19 disease in healthcare professionals with the administration of the IMUNOR® preparation, and decreasing the symptoms should the disease appear.
Detailed Description
This prospective study is designed to collect data for evaluation of the preventive and therapeutic effect of the IMUNOR® preparation, which is commonly used to treat patients with laboratory or clini...
Eligibility Criteria
Inclusion
- Study subjects 18-60 years old
- Ability to cooperate upon the study and to give informed consent
Exclusion
- Use of any other immunomodulation treatment one month prior to enrolment and in the course of the study
- Acute disease of the cardiovascular, urogenital, respiratory or nervous system
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 2 2021
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT04710381
Start Date
February 1 2021
End Date
June 2 2021
Last Update
July 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, Czechia, 70852